Detalle de: Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy
| Title | Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy |
| Abstract |
The digestion of gluten generates toxic peptides, among which a highly immunogenic proline-rich 33-mer from wheat α-gliadin, that trigger coeliac disease. Neprosin from the pitcher plant is a reported prolyl endopeptidase. Here, we produce recombinant neprosin and its mutants, and find that full-length neprosin is a zymogen, which is self-activated at gastric pH by the release of an all-β pro-domain via a pH-switch mechanism featuring a lysine plug. The catalytic domain is an atypical 7+8-stranded β-sandwich with an extended active-site cleft containing an unprecedented pair of catalytic glutamates. Neprosin efficiently degrades both gliadin and the 33-mer in vitro under gastric conditions and is reversibly inactivated at pH > 5. Moreover, co-administration of gliadin and the neprosin zymogen at the ratio 500:1 reduces the abundance of the 33-mer in the small intestine of mice by up to 90%. Neprosin therefore founds a family of eukaryotic glutamate endopeptidases that fulfils requisites for a therapeutic glutenase. |
| Apa Reference | del Amo-Maestro, L., Mendes, S. R., Rodríguez-Banqueri, A., Garzon-Flores, L., Girbal, M., Rodríguez-Lagunas, M. J., Guevara, T., Franch, À., Pérez-Cano, F. J., Eckhard, U., & Gomis-Rüth, F. X. (2022). Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy. Nature Communications, 13(1). 10.1038/s41467-022-32215-1 |
| Doi | 10.1038/s41467-022-32215-1 |
| Publication Date | 1 Aug 2022 |
| Publication Type | Article |
| Researcher | Ulrich Eckhard |
| Ontology | Mutation Analysis and design |
| Research Groups | Synthetic Structural Biology |
| Tools |
